TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16596465
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose risperidone
Study: 11094588
Drug: Rapacuronium 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 2.0 mg kg-1
Study: 11094588
Drug: Rapacuronium 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 2.5 mg kg-1
Study: 11094588
Drug: Succinylcholine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.0 mg kg-1
Study: 11094588
Drug: Rapacuronium 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 2.0 mg kg-1 vs Succinylcholine
Study: 11094588
Drug: Rapacuronium 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 2.5 mg kg-1 vs Succinylcholine
Study: 11094588
Drug: Rapacuronium (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium (both doses)
Study: 1723288
Drug: Early consolidation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early consolidation therapy with 6 courses of CVP (cyclophosphamide, vincristine, prednisone) given monthly
Study: 1723288
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with cyclophosphamide and prednisone given every 6 weeks for 2 years
Study: 7468581
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of human diploid cell strains rabies vaccine (HDCV) administered in three days
Study: 7468581
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of human diploid cell strains rabies vaccine (HDCV) administered in 14 days
Study: 17486918
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus of neuromuscular blocking drug (rocuronium) at induction
Study: 17486918
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of neuromuscular blocking drugs
Study: 15606435
Drug: Lornoxicam (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (8 mg single oral dose)
Study: 7777246
Drug: Ondansetron administered
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron administered in group A: 8 mg IV infusion over 10 min before CDDP, followed by 8 mg orally every 8 h for 3 days.
Study: 7777246
Drug: Ondansetron administered
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron administered in group B: six intravenous doses every 6 h starting 12.5 h before cisplatin, followed by 8 mg orally every 6 h for 3 days.
Study: 2225876
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg urapidil infusion
Study: 21090333
Drug: Medication (Antine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Antine Capsule, diclofenac sodium, 50 mg, twice daily)
Study: 19192762
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of tramadol in 3‐mL saline
Study: 15903126
Drug: Ximelagatran (24,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (24, 36, 48, or 60 mg twice daily for 12 to 16 days)
Study: 10346073
Drug: Sequential assignment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential assignment (SA)
Study: 1659239
Drug: Pentamidine injections
Normalized name: pentamidine Injection
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentamidine injections followed by 20 days of sodium stibogluconate therapy
Study: 1659239
Drug: Pentamidine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine (5 additional injections) followed by a course of antimony therapy
Study: 6797298
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg + Oxyphenonium bromide 10 mg
Study: 31842950
Drug: Tetramethylpyrazine (TMP)
Normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetramethylpyrazine (TMP) 100 mg orally three times a day for 16 weeks
Study: 26175552
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation (BP)
Study: 26175552
Drug: Non-bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-bowel preparation (NP)
Study: 9504599
Drug: Melatonin 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3.0 mg nightly for 30 days
Study: 1239216
Drug: Bupivacaine and
Normalized name: bupivacaine and meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine and saline solution
Study: 21639660
Drug: No videotape
Approvals — FDA: no, EMA: no, PMDA: no
Description: No videotape treatment-as-usual
Study: 12876237
Drug: Entacapone 200
Normalized name: entacapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone 200 mg with each daily levodopa dose
Study: 8712328
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.0625% bupivacaine with either 2.5 micrograms.ml‐1 fentanyl or 0.25 micrograms.ml‐1 sufentanil
Study: 30821716
Drug: Sustained nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained nicorandil administration (5 mg, three times daily)
Study: 30821716
Drug: Single nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single nicorandil administration before PCI (control group)
Study: 30821716
Drug: Sustained nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained nicorandil administration
Study: 21864866
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and glucose administration
Study: 3915155
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 250 mg mefloquine
Study: 3915155
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 500 mg mefloquine
Study: 3915155
Drug: Standard 3-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 3-day treatment with 1,500 mg chloroquine
Study: 30865324
Drug: Strong Hearts,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strong Hearts, Healthy Communities (SHHC) intervention; met 1 hour twice a week for 24 weeks, involving aerobic exercise and progressive strength training.
Study: 20929110
Drug: HTK solution
Normalized name: Custodial HTK Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTK solution (nonflushed)
Study: 20929110
Drug: HTK solution
Normalized name: Custodial HTK Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTK solution (flushed)
Study: 15661405
Drug: Purging with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purging with 25 mug/mL ET‐18‐OCH3 combined with cryopreservation at 10% DMSO and hyperthermia at 42 degrees C combined with cryopreservation at 10% or 4% DMSO
Study: 12232643
Drug: 0.01 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg cisatracurium (Cis 6 group: pretreatment interval 6 min)
Study: 12232643
Drug: 0.01 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg cisatracurium (Cis 3 group: pretreatment interval 3 min)
Study: 10705622
Drug: Short-term hormone
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term hormone replacement therapy (< 10 months)
Study: 10705622
Drug: Long-term hormone
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term hormone replacement therapy (> 11 months)
Study: 1746257
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml normal saline solution
Study: 1746257
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml normal saline solution
Study: 1746257
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml normal saline solution
Study: 1746257
Drug: Oxytocin 10
Normalized name: oxytocin 10 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 10 units in 20 ml saline solution
Study: 1746257
Drug: Oxytocin 10
Normalized name: oxytocin 10 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 10 units in 40 ml saline solution
Study: 7064040
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of lignocaine
Study: 31367893
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy + Balneotherapy (PT + BT)
Study: 31367893
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy alone (PT)
Study: 28805022
Drug: Hesperidin 500
Normalized name: Ascorbic Acid/Bioflavonoid/Hesperidin 500 MG-100 MG-100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hesperidin 500 mg/day for 6 weeks
Study: 25622744
Drug: Dexmedetomidine preconditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine preconditioning (Pre-Dex group) - intravenous infusion at a dose of 0.125 ml/kg (4 µg/ml) for 10 minutes before tourniquet use.
Study: 3737040
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment before repeat cytology
Study: 17900705
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs (EPA+DHA) 3 g daily for 3 months
Study: 11895159
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (enteral and parenteral)
Study: 2671220
Drug: Oxymetazoline (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline (doses and concentrations traditionally used)
Study: 28431060
Drug: Chronic antiarrhythmic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic antiarrhythmic drug (AAD) therapy with bisoprolol (5 mg od) and/or diltiazem (120-300 mg od)
Study: 28431060
Drug: Chronic antiarrhythmic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic antiarrhythmic drug (AAD) therapy
Study: 25288674
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (INI) 40 IU
Study: 23117071
Drug: Trabectedin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 1.5 mg/m² (24‐h infusion every 3 weeks)
Study: 17100937
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg (2 x 50 mg encapsulated tablets)
Study: 15149510
Drug: Inositol supplements
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol supplements
Study: 11522873
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous iron infusions (200 mg every 2 months)
Study: 11522873
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral iron supplements (210 mg elemental iron per day)
Study: 9050955
Drug: Mitoxantrone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (8 mg/m2 I.V. infusion every month for 1 year)
Study: 9050955
Drug: Placebo (I.V.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (I.V. infusion of saline every month for 1 year)
Study: 30640245
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol (3 mg/kg)
Study: 30640245
Drug: Peritonsillar infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar infiltration with bupivacaine (5 ml, 0.25%)
Study: 26643993
Drug: GSK1278863 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863 50 mg
Study: 26643993
Drug: GSK1278863 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863 100 mg
Study: 26643993
Drug: GSK1278863 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863 (10 to 100 mg)
Study: 23821414
Drug: Riluzole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (50 or 100 mg/day based on bodyweight) + Risperidone (up to 2 or 3 mg/day based on bodyweight)
Study: 23821414
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Risperidone (up to 2 or 3 mg/day based on bodyweight)
Study: 7923646
Drug: Hirudin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (0.4 mg/kg body wt bolus and 0.15 mg.kg‐1.h‐1) infused over 48 to 72 hours
Study: 7923646
Drug: Heparin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (70 IU/kg body wt bolus and 15 IU.kg‐1.h‐1) infused over 48 to 72 hours
Study: 3347519
Drug: Vasoactive drugs
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive drugs or mechanical ventilation
Study: 3347519
Drug: Cardiac index
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac index less than 2.3 L/min/m2
Study: 28499707
Drug: L‐SMILE (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐SMILE (low energy: 100, 105, and 110 nJ)
Study: 20881376
Drug: Erythromycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (125 mg, three times/day)
Study: 18245068
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous patient-controlled analgesia (PCA)
Study: 17001944
Drug: Urgotul wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urgotul wound dressing with TNP therapy
Study: 1598464
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg acetylsalicylic acid
Study: 1598464
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg acetylsalicylic acid plus 75 mg dipyridamole
Study: 2856892
Drug: Nadolol 10
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol 10 mg
Study: 30160168
Drug: BMAC injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMAC injection
Study: 22350194
Drug: Long-term Internet-delivered
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term Internet-delivered worksite health promotion programme with additional website functionalities (action-oriented feedback, self-monitoring, possibility to ask questions, monthly e-mail messages)
Study: 19126830
Drug: Instalment prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instalment prescription (n = 101)
Study: 19126830
Drug: Normal prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal prescription (n = 103)
Study: 14747671
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg daily iron supplementation
Study: 14747671
Drug: Mebendazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (500 mg) every 3 months
Study: 8993242
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (group B)
Study: 27181129
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment based on TCM diagnosis
Study: 23354913
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care treatment
Study: 15879586
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic drugs (olanzapine, perospirone, quetiapine, or risperidone)
Study: 12939003
Drug: Mandibular implant-retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mandibular implant-retained overdenture (IOD)
Study: 10930055
Drug: Sodium polystyrene
Normalized name: Sodium Polystyrene Sulfonate
DrugBank: Tolevamer (DB01344)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium polystyrene sulfonate 30 g
Study: 8689424
Drug: Interleukin-6 (IL-6)
Normalized name: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-6 (IL-6) daily bolus therapy
Study: 8689424
Drug: Interleukin-6 (IL-6)
Normalized name: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-6 (IL-6) continuous infusion (C.I.) therapy
Study: 8689424
Drug: Interleukin-6 (IL-6)
Normalized name: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-6 (IL-6) bolus therapy
Study: 31553410
Drug: Inclisiran (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (1 dose: 200, 300, or 500 mg on day 1)
Study: 31553410
Drug: Inclisiran (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (2 doses: 100, 200, or 300 mg on days 1 and 90)
Study: 31553410
Drug: Inclisiran (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (2 doses: 300 mg)
Study: 31553410
Drug: Inclisiran (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (1 or 2 doses)
Study: 29235159
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea ointment
Study: 22506760
Drug: Higher energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher energy treatment with cryogen spray cooling (CSC) (10‐mm spot size; 50 J/cm(2); 50‐ms pulse duration and CSC settings of 30‐ms duration with a 20‐ms delay)
Study: 22506760
Drug: Lower energy
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower energy treatment with no CSC (10 mm; 20 J/cm(2); 50 ms)
Study: 17506788
Drug: Concurrent oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent oxytocin infusion with dinoprostone pessary
Study: 12082182
Drug: Treatment using
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment using computer support to train patients to eat and recognize satiety, with physical activity restriction and resting in a warm room after eating.
Study: 12082182
Drug: Treatment to
Normalized name: Lice Treatment Topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment to remission.
Study: 6626409
Drug: Rectal solution
Normalized name: Rectal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal solution including diazepam 0.5 mg kg‐1, morphine 0.15 mg kg‐1 and hyoscine 0.01 mg kg‐1 (Group B)
Study: 29779922
Drug: IM-HA/D (Intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM-HA/D (Intramuscular injection of Fluvax® 2016), n=15
Study: 24464551
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Sofosbuvir and GS-0938
Study: 19558807
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose ACTH therapy (50 IU per day for 2 weeks, then tapered to zero over 2 weeks)
Study: 19558807
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ACTH therapy (0.4 IU/kg per day for 2 weeks, then tapered to zero over 2 weeks; dosage increased to 1 IU/kg per day if no effective response)
Study: 19558807
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose ACTH therapy
Study: 19558807
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ACTH therapy
Study: 19558807
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Conventional and Low dose ACTH therapy)
Study: 11339019
Drug: Hyperthyroid patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthyroid patients (pre-treatment)
Study: 11339019
Drug: Hyperthyroid patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthyroid patients (post-treatment)
Study: 8783690
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg on days 1‐5 and 10 (total dose, 24 mg/kg)
Study: 8783690
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg on days 1‐5 and 10 (total dose, 18 mg/kg)
Study: 8783690
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg on days 1‐4 and 10 (total dose, 15 mg/kg)
Study: 8783690
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg for 10 days
Study: 8783690
Drug: 12 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/kg total dose
Study: 6714287
Drug: Hydergine special
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine special (1 x 4 mg)
Study: 6714287
Drug: Hydergine forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine forte (2 x 2 mg)
Study: 25840767
Drug: Nebulized fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized fentanyl (2 μg/kg)
Study: 23123043
Drug: Specific medical
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific medical food (400 ml daily for one week, high in protein and leucine, enriched with fish oil and specific oligosaccharides)
Study: 18206175
Drug: Folate treatment
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate treatment (5 mg folic acid per day, 50 mg vitamin B6 per day, 1,000 microg vitamin B12 per day)
Study: 11083735
Drug: Metoprolol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol treatment for 12 months
Study: 8866582
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray ad libitum (n=45)